Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin, Nivolumab, and R-CHP in Untreated Primary Mediastinal Large B-Cell Lymphoma
NCT04745949Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2021
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin, nivolumab in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by University of Texas MD Anderson Cancer Center. Started May 2021; status: recruiting.
02
Drugs
brentuximab vedotinnivolumab
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT04745949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04745949.